Impedance of Novel Therapeutic Technologies: The Case of Stem Cells

David G. Zacharias, Timothy J Nelson, Paul Mueller, C. Christopher Hook

Research output: Contribution to journalArticle

Abstract

Embryonic stem cell (ES) technology has advanced considerably within the past three decades and has gained prominent distinction within the emerging field of regenerative medicine. As it now enters the nascent stages of clinical application, many hopes and expectations arise along with questions as to where the technology will go. This paper evaluates the technical and practical obstacles that must be overcome before it can fully translate into the clinical context, the existence of strong opposition to the technology, political and legal barriers that have impeded its progression, and the role of healthcare reform in creating new social and economic priorities. In contrast to the technological imperative, a driving force seeking to implement the most recent scientific advances into medical practice, we refer to such translational obstacles as "technological impedance." Rather than expending inordinate effort to preserve existing systems that continue to possess major hurdles, we advocate fostering interdisciplinary approaches in the development of new generation platforms and embracing disruptive innovations that create solutions to technological impedance and move us forward in healthcare delivery.

Original languageEnglish (US)
Pages (from-to)422-427
Number of pages6
JournalClinical and Translational Science
Volume5
Issue number5
DOIs
StatePublished - Oct 2012

Fingerprint

Stem cells
Electric Impedance
Stem Cells
Technology
Regenerative Medicine
Foster Home Care
Health Care Reform
Embryonic Stem Cells
Therapeutics
Innovation
Economics
Delivery of Health Care

Keywords

  • Biomedical ethics
  • Human embryonic stem cells
  • Induced pluripotent stem cells
  • Regenerative medicine

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Impedance of Novel Therapeutic Technologies : The Case of Stem Cells. / Zacharias, David G.; Nelson, Timothy J; Mueller, Paul; Hook, C. Christopher.

In: Clinical and Translational Science, Vol. 5, No. 5, 10.2012, p. 422-427.

Research output: Contribution to journalArticle

@article{47d9f1f4c4e04bd98764548a25db1183,
title = "Impedance of Novel Therapeutic Technologies: The Case of Stem Cells",
abstract = "Embryonic stem cell (ES) technology has advanced considerably within the past three decades and has gained prominent distinction within the emerging field of regenerative medicine. As it now enters the nascent stages of clinical application, many hopes and expectations arise along with questions as to where the technology will go. This paper evaluates the technical and practical obstacles that must be overcome before it can fully translate into the clinical context, the existence of strong opposition to the technology, political and legal barriers that have impeded its progression, and the role of healthcare reform in creating new social and economic priorities. In contrast to the technological imperative, a driving force seeking to implement the most recent scientific advances into medical practice, we refer to such translational obstacles as {"}technological impedance.{"} Rather than expending inordinate effort to preserve existing systems that continue to possess major hurdles, we advocate fostering interdisciplinary approaches in the development of new generation platforms and embracing disruptive innovations that create solutions to technological impedance and move us forward in healthcare delivery.",
keywords = "Biomedical ethics, Human embryonic stem cells, Induced pluripotent stem cells, Regenerative medicine",
author = "Zacharias, {David G.} and Nelson, {Timothy J} and Paul Mueller and Hook, {C. Christopher}",
year = "2012",
month = "10",
doi = "10.1111/j.1752-8062.2012.00434.x",
language = "English (US)",
volume = "5",
pages = "422--427",
journal = "Clinical and Translational Science",
issn = "1752-8054",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Impedance of Novel Therapeutic Technologies

T2 - The Case of Stem Cells

AU - Zacharias, David G.

AU - Nelson, Timothy J

AU - Mueller, Paul

AU - Hook, C. Christopher

PY - 2012/10

Y1 - 2012/10

N2 - Embryonic stem cell (ES) technology has advanced considerably within the past three decades and has gained prominent distinction within the emerging field of regenerative medicine. As it now enters the nascent stages of clinical application, many hopes and expectations arise along with questions as to where the technology will go. This paper evaluates the technical and practical obstacles that must be overcome before it can fully translate into the clinical context, the existence of strong opposition to the technology, political and legal barriers that have impeded its progression, and the role of healthcare reform in creating new social and economic priorities. In contrast to the technological imperative, a driving force seeking to implement the most recent scientific advances into medical practice, we refer to such translational obstacles as "technological impedance." Rather than expending inordinate effort to preserve existing systems that continue to possess major hurdles, we advocate fostering interdisciplinary approaches in the development of new generation platforms and embracing disruptive innovations that create solutions to technological impedance and move us forward in healthcare delivery.

AB - Embryonic stem cell (ES) technology has advanced considerably within the past three decades and has gained prominent distinction within the emerging field of regenerative medicine. As it now enters the nascent stages of clinical application, many hopes and expectations arise along with questions as to where the technology will go. This paper evaluates the technical and practical obstacles that must be overcome before it can fully translate into the clinical context, the existence of strong opposition to the technology, political and legal barriers that have impeded its progression, and the role of healthcare reform in creating new social and economic priorities. In contrast to the technological imperative, a driving force seeking to implement the most recent scientific advances into medical practice, we refer to such translational obstacles as "technological impedance." Rather than expending inordinate effort to preserve existing systems that continue to possess major hurdles, we advocate fostering interdisciplinary approaches in the development of new generation platforms and embracing disruptive innovations that create solutions to technological impedance and move us forward in healthcare delivery.

KW - Biomedical ethics

KW - Human embryonic stem cells

KW - Induced pluripotent stem cells

KW - Regenerative medicine

UR - http://www.scopus.com/inward/record.url?scp=84867735184&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867735184&partnerID=8YFLogxK

U2 - 10.1111/j.1752-8062.2012.00434.x

DO - 10.1111/j.1752-8062.2012.00434.x

M3 - Article

C2 - 23067356

AN - SCOPUS:84867735184

VL - 5

SP - 422

EP - 427

JO - Clinical and Translational Science

JF - Clinical and Translational Science

SN - 1752-8054

IS - 5

ER -